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Abstract 
Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer in 
both men and women.  A recent phase IIb study demonstrated that disulfiram (DSF) 
in combination with cisplatin and vinorelbine was well tolerated and prolonged the 
survival of patients with newly diagnosed NSCLC. However, DSF is rapidly (4 
minutes) metabolised in the bloodstream and it is this issue which is limiting its 
anticancer application in the clinic.  We have recently demonstrated that a low dose 
of DSF-loaded PLGA nanoparticles supplemented with oral Cu inhibited tumour 
growth and reduced metastasis in a xenograft mouse lung cancer model.  Here we 
demonstrate the influence of PLGA polymer, stabilizer loading and molecular weight 
as well as sonication time on the characteristics, including DSF release and the 
cytotoxicity of 10% w/w DSF-loaded PLGA nanoparticles.  The paper demonstrates 
that the choice of PLGA as no significant influence on the characteristics of the 
nanoparticles apart from their DSF release, which is due to the differing degradation 
rates of the polymers.  However, increasing the loading and molecular weight of the 
stabilizer as well as the sonication time reduced the size of the nanoparticles, 
reduced their ability to protect the DSF from reacting with Cu and degrading in 
serum, while increasing their DSF release rate and cytotoxicity.  Additionally, 
increasing the sonication time resulted in the premature degradation of the PLGA, 
which increased the permeability of the nanoparticles further decreasing their ability 
to protect DSF from reacting with Cu and degrading in serum, while increasing their 
DSF release rate and cytotoxicity.  
1. Introduction 
Lung cancer is the second most common cancer in both men and women behind 
prostrate and breast cancer respectively [1].  There were more than 1.8 million new 
cases (13% of total cancer incidence) and almost 1.6 million deaths (20% of total 
cancer mortality) globally [1]. Lung cancer is categorised into two types, non-small 
cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC 
accounting for 87% of lung cancer cases [2].  The prognosis for NSCLC patients is 
poor with only 15% of patients surviving longer than 5-years and a high rate of 
recurrence [3-5].  
Current treatment options for NSCLC are radiotherapy and chemotherapy, both 
which have their limitations such as toxicity, serious systemic side-effects, low 
selectivity and resistance [6].  The systemic administration of chemotherapeutic 
drugs has its limitations due to the need for higher dose, which result in serious 
adverse side-effects as these drugs destroy both cancerous and healthy cells [7-8]. 
Encapsulating a chemotherapeutic drug in a nanoparticle offers a number of 
advantages, such as protection from degradation in the blood stream, improved drug 
solubility, targeted drug delivery, decreased side-effects, increased drug exposure 
time and reduced drug resistance.  Nanoparticles tend to be manufactured using 
biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) or polycaprolactone 
(PCL) and have been shown to have increased efficacy and reduced toxicity 
compared to conventional delivery of chemotherapeutic drugs [9].  If designed 
correctly nanoparticle formulations can be made to accumulate in cancerous tissue 
by either passive or active targeting without being excreted from the body [10].  The 
small size of the nanoparticles allows them to accumulate in tumours by 
extravasation due to leaky vasculature and a poorly developed lymphatic drainage 
system [11-12].  Poorly designed nanoparticles will be taken up by the 
reticuloendothelial system (RES) of the body.  Nanoparticles with a hydrophobic 
surface are rapidly taken up by the liver, spleen and lungs [13], while those with a 
hydrophilic surface showed an increased circulation time in the body [14].  Therefore, 
to achieve increased circulation time in the bloodstream and thus improved targeting, 
nanoparticles need to be 100M or less is size with a hydrophilic surface in order to 
reduce clearance by macrophages [15].  Paclitaxel nanoparticles have been shown 
to have similar efficacy, with faster administration times, when compared to 
conventional formulations in preclinical studies [16-17].  Doxorubicin-loaded PLGA 
nanoparticles where targeted to A549 lung cancer cells by the attachment of a 
CXCR4 antagonist (LFC131 peptide) to their surface [18].   
NSCLC and other cancers contain a small population of Cancer Stem Cells (CSCs) 
which are resistant to radio- and chemotherapy and are responsible for cancer 
recurrence [19-20]. Therefore the discovery of a CSC-targeting drug would 
significantly improve chemotherapy outcomes for NSCLC patients. The anti-
alcoholism drug disulfiram (DSF) has been shown to have an anticancer effect 
against prostate cancer, breast cancer, brain tumours, leukaemia, cervical 
adenocarcinoma and NSCLC [21-34].  Furthermore, DSF has been shown to be an 
irreversible aldehyde dehydrogenase (ALDH) inhibitor targeting CSCs [22, 35-36]. 
This anticancer effect is copper (Cu) dependent [37-38] as Cu plays a crucial role in 
redox reactions which trigger the generation of reactive oxygen species (ROS) 
inducing apoptosis in human cells [39].  A recent phase IIb study demonstrated that 
DSF in combination with cisplatin and vinorelbine was well tolerated and prolonged 
the survival of patients with newly diagnosed NSCLC [40]. DSF chelates Cu(II) 
forming a DSF/Cu complex increasing the transport of Cu into cancer cells and is a 
much stronger ROS inducer than Cu alone [41-42].  Drug induced ROS 
accumulation can be counterbalanced by the activation of NFκB, which inhibits ROS 
and ROS-induced cytotoxicity [43] but DSF inhibits the activity of NFκB [44].  For this 
anticancer effect to occur to DSF must accumulate in the cancer cell in its unaltered 
form and chelate with copper in the cancer cell. However, DSF is rapidly (4 minutes) 
metabolised in the bloodstream and it is this issue which is limiting its anticancer 
application in the clinic.  Therefore, a drug delivery system which protects DSF from 
metabolism in the blood stream and targets it to NSCLC cells would expedite 
translation of DSF into the clinic as a treatment for NSCLC.  To this end, we recently 
formulated DSF into liposomes, PLGA and gold nanoparticles, which at very low 
dose in combination with an oral Cu supplement demonstrated a significant tumour 
inhibiting effect in xenograft mouse models of breast and lung cancer [36, 45].  
Furthermore, we also recently demonstrated that PLGA nanoparticles can extend the 
half-life of DSF in blood from under 2 minutes to 7 hours.  The DSF-loaded PLGA 
nanoparticles in combination with copper significantly inhibited the liver CSC 
population and demonstrated very promising anticancer efficacy and anti-metastatic 
effect in a liver cancer mouse model [46]. 
In this study we will investigate the influence of the PLGA type, sonication time, the 
amount and molecular weight of stabiliser on the morphology, particle size, zeta 
potential, encapsulation efficiency, drug release, the ability to protect DSF and 
cytotoxicity against lung cancer of DSF-loaded PLGA nanoparticles.   
  
2. Materials and Methods 
2.1. Materials 
Poly (D,L-lactide-co-glycolide) (PLGA) was purchased from Evonik (Birmingham, AL, 
USA), while Polyvinyl acetate (PVA), Disulfiram (DSF), Dichloromethane (DCM), 
Tween 80, Sucrose, Phosphate-buffered saline (PBS) (pH 7.4), Methanol and 
Copper (Cu), were all purchased from Sigma-Aldrich (Dorset, UK). 
2.2. Preparation of the 10% w/w DSF-loaded PLGA nanoparticles 
10% w/w DSF loaded PLGA nanoparticles were prepared using the emulsion-solvent 
evaporation method. 50mg of DSF and 450mg of PLGA were dissolved in 10ml of 
DCM. 100mg of PVA was dissolved in 25ml of water at 40°c using a hotplate stirrer 
and the PLGA/DSF solution added drop wise using a burette with an 18G needle 
and left to stir for 30 minutes. The subsequent solution was probe-sonicated 9 times 
for 3 minutes at 60% power, and left to stir at 40°c overnight to remove the residual 
DCM. The nanoparticle solutions were centrifuged at 9500 rpm for 20 minutes and 
the supernatant removed. The pellets were re-suspended in 25ml of distilled water 
and centrifuged and the supernatant removed. This wash-step was repeated one 
more time. Finally the washed nanoparticles were suspended in 10ml of 1% sucrose 
and placed in the freezer overnight to freeze. The frozen solution was freeze dried 
for 72 hours, with the primary drying stage lasting 48 hours at 0.5 millibar and the 
secondary drying stage 24 hours at 0.35 millibar. The dried nanoparticles were 
stored in the fridge until required.  The above procedure was repeated with the type 
of PLGA, sonication time, amount and molecular with of PVA varied as per table 1. 
 
 2.3. Morphology and size of the 10% w/w DSF-loaded PLGA nanoparticles 
Scanning Electron Microscopy (SEM) images of the 10% w/w disulfiram loaded 
PLGA nanoparticles where taken using a Zeiss EV050-EP scanning electron 
microscopy.  A small amount of each nanoparticle sample was placed onto an 
aluminium stub using an adhesive carbon tab then sputter-coated with gold. 
2.4. Particle size and zeta potential of the 10% w/w DSF-loaded PLGA Nanoparticles 
Particle size and zeta potential were measured by photon correlation spectroscopy 
using a Zetasizer HAS 3000 from Malvern (Worecestershire, UK). 100 μL of the 
nanoparticle suspension was dispersed in 4 mL deionized water and sonicated for 1 
min. Measurements were carried out at 25 °C. 
2.5. Encapsulation efficiency of the 10% w/w DSF-loaded PLGA nanoparticles 
Encapsulation efficiency was determined by dissolving 5mg of each nanoparticle 
formulation (n=5) in DCM.  The DCM was evaporated overnight and the residue 
dissolved in ethanol.  The ethanol was filtered (pore size 0.22 m, Millipore) and 
subsequently analysed using the stability indicating DSF HPLC method. 
2.6. In- vitro release of the 10% w/w DSF-loaded PLGA nanoparticles 
Each 10% w/w disulfiram loaded PLGA nanoparticle formulation (n=5) was placed 
into a dialysis bag containing 3ml of 1% w/v tween solution. The dialysis bag was 
subsequently placed into a glass beaker containing 22ml of 1% w/v tween solution. 
300μL samples were taken once every day for 7 days and replaced with 300μL of 
fresh 1% tween. The samples were subsequently analysed using the stability 
indicating DSF HPLC method.  
2.7. Effect of copper on the 10% w/w DSF-loaded PLGA nanoparticles 
5mg of each 10% w/w disulfiram loaded PLGA nanoparticle formulation (n=5) was 
placed into 1ml of PBS containing 10ul of copper and left for 72 hours. The PBS was 
centrifuged 10,000rpm for 5 minutes, the supernatant removed and the precipitated 
particles washed with 1ml of distilled water, centrifuged again and supernatant 
removed. The particles were dissolved in DCM and left overnight for the DCM to 
evaporate.  The residue was dissolved in ethanol, filtered (pore size 0.22 m, 
Millipore) and subsequently analysed using the stability indicating DSF HPLC 
method. 
2.8. Determination of the serum half-life of DSF in the 10% w/w DSF-loaded PLGA 
nanoparticles. 
To determine the half-life of encapsulated DSF 5mg of each 10% w/w disulfiram 
loaded PLGA nanoparticle formulation (n=5) was added into an eppendorf tube 
containing 300 l of horse serum with shaking at 37°C. At set time intervals (2, 4, 10, 
20, 30, 60 and 120 minutes) the eppendorf tubes were centrifuged at 10,000 rpm for 
5 minutes, the supernatant removed and the precipitated particles washed with 1ml 
of distilled water, centrifuged again and supernatant removed. The particles were 
dissolved in DCM and left overnight for the DCM to evaporate.  The residue was 
dissolved in ethanol, filtered (pore size 0.22 m, Millipore) and subsequently 
analysed using the stability indicating DSF HPLC method..  The stability of the DSF 
in the supernatant was determined using the stability indicating DSF HPLC method.  
 
 
2.9. DSF Stability Indicating HPLC Method 
HPLC analysis was performed on an Agilent 1200 series HPLC (Agilent, Santa 
Clara, CA) with a Phenomenex Luna C18 4.6 × 150 mm2 column with a 5-:M particle 
size (Phenomenex, Torrance, CA). The mobile phase comprises 80% HPLC grade 
methanol and 20% HPLC grade water. The flow rate was 1.00 mL/min, whereas UV 
detection was performed at a wavelength of 275 nm with an injection volume of 
10L. 
2.10. The cytotoxicity of the 10% w/w DSF-loaded PLGA nanoparticles against 
NSCLC cells 
For in-vitro cytotoxicity analysis, the overnight cultured A549 lung cancer cells 
(5000/well in 96-well flat-bottomed microtitre plates) were constantly exposed to 
different concentrations of the 10% w/w DSF-loaded PLGA nanoparticles with the 
same concentration (10 μm) of CuCl2 for 72 h and then subjected to a standard 3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay as 
previously described [47].  Unformulated DSF was used as a control, the 
experiments repeated three times and the 50% inhibitory concentrations (IC50) were 
calculated.  
2.11. Statistical Analysis 
Statistical analysis was performed using a one way analysis of variance (ANOVA) 
(GraphPad Prism version 5.02 for Windows, GraphPad Software, San Diego, CA).  
Post-hoc comparisons of the means were performed using Tukey’s Honestly 
Significance Difference test.  A significance level of p < 0.05 was accepted to denote 
significance in all cases  
3. Results and Discussion 
3.1. Surface morphology, particle size and zeta potential of the 10% w/w DSF-loaded 
PLGA nanoparticles 
The surface morphology of the 10% w/w DSF-loaded PLGA nanoparticles was 
analysed using SEM and a representative SEM image is presented in figure 1.  The 
SEM image demonstrates that the nanoparticle formulations were spherical in 
shape, had a well-defined structure, a smooth surface with no pitting and did not 
aggregate together in small clusters. The smooth surface of the nanoparticles would 
indicate that there is no DSF on their surface, which suggests that the DSF was fully 
encapsulated and any excess washed away during preparation. Free DSF on the 
surface of the particle would mean less DSF was encapsulated and will influence 
DSF release resulting in an ‘initial burst’ [48].  Pitting can influence the durability and 
integratory of the nanoparticles [49] and tends to occur in acidic pH making the 
PLGA more porous and causing accelerated degradation, resulting in increased drug 
release, which could mean that a lower concentration of the drug will reach the target 
cell [50].  Aggregated nanoparticles are much more difficult to disperse making 
systemic administration difficult. 
All of the nanoparticle formulations where in the nanoscale size range and their size 
ranged from 145.2 to 208.4nm depending on the formulation and sonication time 
used (Table 2).  The choice of PLGA had no significant effect on the size of the 
nanoparticles (p < 0.05) (Figure 2A), while increasing the PVA loading (Figure 2A) 
and sonication time (Figure 2B) significantly decreased the size of the nanoparticles 
(p > 0.05).  Increasing the molecular weight of the PVA from 10 to 75 KDa had no 
significant influence on their size (p < 0.05) (Figure 2B).  However, when the 
molecular weight of the PVA was increased to 120 KDa their size was significantly 
reduced (p < 0.05) (Figure 2B).  Increasing the PVA loading reduces particle size by 
increasing the stabilisation of the nanoparticles reducing aggregation, which in turn 
reduces the formation of larger particles [51]. Increasing the sonication time reduces 
the particle size by increasing shear stress, as a result of the longer sonication time, 
which increases droplet breakdown reducing the size of the particle [52].  Increasing 
the molecular weight of the PVA decreased the particle size because at a high 
molecular weight the PVA has less interaction with the aqueous phase thus further 
stabilizing the nanoparticles and reducing their size [51]. 
Zeta potential is a measure of the charge on the surface of a nanoparticle and can 
be used as an indicator of nanoparticle stability.  When the surface charge is high 
there is a strong electrostatic repulsion between the nanoparticles, which results in 
reduced aggregation [53-54]. The minimum zeta potential required for stability is ±30 
mV and all of the nanoparticles were positively charged with a zeta potential range of 
+35.2 to +57.5mV (Table 2).   Furthermore, zeta potential is an important feature in 
relation to the interaction of nanoparticles with cell membranes which is influenced 
by the surface charge of the nanoparticles [55].  The overall surface charge of 
cancer cells is normally negative [53] and positively charged nanoparticles strongly 
bind to the negatively charged cell membrane. Furthermore, positive nanoparticles 
have a much greater cytotoxicity compared to neutral nanoparticles due to being 
more efficient at penetrating and crossing the cell membrane of the cancer cell 
through endocytosis [55-57].  There was no correlation between zeta potential and 
the choice of PLGA, PVA loading, sonication time or PVA molecular weight (Table 
2).   
 
3.2. Encapsulation efficiency of the 10% w/w DSF-loaded PLGA nanoparticles 
The encapsulation efficiency of the nanoparticles ranged from 69 to 94% depending 
on the choice of formulation and sonication time (Figures 2C and D).  The choice of 
PLGA polymer had no significant (p > 0.05) influence on the encapsulation efficiency 
of the nanoparticles (Figure 2C).  This is not surprising as all three polymers had the 
same ratio (50:50) of lactide to glycolide and similar molecular weights.  The choice 
of PLGA can influence encapsulation efficiency but only when lactide to glycolide 
ratio or molecular weight varies.  A PLGA with a high lactide to glycolide ratio or a 
low molecular weight will be highly soluble in the organic solvent, which can result in 
low encapsulation efficiencies [58].  As the PVA loading increased the encapsulation 
efficiency of the nanoparticles significantly decreased (p < 0.05) (Figure 2C).  This is 
due to the size of the nanoparticles decreasing with an increase in PVA loading 
(Figure 2A).  The smaller the size of the nanoparticles the less DSF they can 
encapsulate and thus the lower the encapsulation efficiency [59].  Furthermore, 
increasing the loading of PVA increases the concentration of residual PVA [60], 
which binds to the DSF limiting it’s encapsulation in the PLGA [61].  Increasing the 
molecular weight of the PVA significantly decreased (p < 0.05) the encapsulation 
efficiency of the nanoparticles (Figure 2D), which again is due to the reduction in the 
size of the nanoparticles (Figure 2B), limiting the amount of DSF they can 
encapsulate.  The longer the sonication time the lower the encapsulation efficiency 
of the nanoparticles (Figure 2D), which like PVA loading and molecular weight is due 
to a reduction in their size.  However, it has also been demonstrated that increasing 
the sonication time can cause the PLGA polymer to prematurely degrade increasing 
its permeability, causing the drug to diffuse out during washing [62]. 
 
3.3. In vitro DSF release from the 10% w/w DSF-loaded PLGA nanoparticles  
In vitro release of DSF from the PLGA nanoparticles over 7 days is presented in 
figure 3.   All of the nanoparticle formulations had diffusion controlled release profiles 
typically associated with PLGA nanoparticles (Figure 3).  The choice of PLGA had a 
significant (p < 0.05) influence on the release of DSF from the nanoparticles (Figure 
3A), which is due to the degradation rate of the PLGA.  DLG 1E has a degradation 
rate of days, while DLG 4A and 4E have degradation rates of weeks and months 
respectively.  We have previous demonstrated that the choice of PLGA polymer can 
influence the release of DSF from PLGA based devices [31-32].  Increasing the 
loading of PVA in the formulation significantly (p < 0.05) increased the release rate of 
DSF from the nanoparticles (Figure 3B).  This is due to a decrease in the size of the 
nanoparticles with an increase in PVA loading (Figure 2A), which results in an 
increase in their overall surface area.  This increase in surface area resulted in a 
significant (p < 0.05) increase in the day 1 burst for the nanoparticles containing 8% 
w/w PVA when compared to the nanoparticles containing either a 2 or 4% w/w PVA 
loading (Figure 3B).  The was no significant (p > 0.05) difference in the release of 
DSF from day 1 to day 5 for the nanoparticles containing PVA with a molecular 
weight of 10 and 75 KDa (Figure 3C).  This is due to these nanoparticles being of 
similar size (Figure 2B).  However, when the molecular weight of the PVA was 
increased to 120 KDa the release of DSF significantly (p < 0.05) increased (Figure 
3C) due to the reduced particle size of the nanoparticles (Figure 2B), which resulted 
in an increase in their overall surface area.  This is demonstrated by a dramatic 
increase in their day 1 burst when compared to the nanoparticles containing PVA 
with a molecular weight of 10 and 75 KDa (Figure 3C).  Increasing sonication time 
significantly (p < 0.05) increased the release of DSF from the nanoparticles (Figure 
3D) again due to a decrease in their size (Figure 2B), which results in an increase in 
their overall surface area.  There is a substantial increase in the day 1 burst of the 
nanoparticles sonicated for 9 minutes when compared to those sonicated for 3 and 6 
minutes (Figure 3D).  The reduced size of the nanoparticles and  increase in overall 
surface area is a contributing factor.  However, another contributing factor is the 
increased permeability of the nanoparticles due to premature degradation of the 
PLGA associated with the increased sonication time [62].   
3.4. The ability of the 10% w/w DSF-loaded PLGA nanoparticles to protect DSF from 
the premature chelating of copper 
The anticancer effect of DSF has been shown to be Cu dependent [37-38] and due 
to cancer cells having increased copper levels compared to normal cells [63] DSF 
demonstrates selectivity towards cancer cells compared to normal cells.  We have 
recently demonstrated that DSF has two mechanisms of action for killing cancer 
cells: 1) Instant cell death caused by the generation of ROS as a result of the 
DSF/Cu reaction and 2) Delayed cell death caused by the cytotoxic nature of the 
DSF/Cu complex [64].  However, in order for these mechanisms to be effective the 
DSF/Cu reaction must take place within the cancer cell.  Therefore, it is imperative 
that the nanoparticles protect the DSF from reacting with Cu outside of the cancer 
cell.   
Figure 4 demonstrates that the encapsulation of DSF into PLGA nanoparticles 
provides protection from copper in comparison with an unformulated DSF control.  
However, the level of protection does depend on the formulation and sonication time 
used.  The choice of PLGA has no significant (p > 0.05) influence on the level of DSF 
protection that the nanoparticles provide (Figure 4A), which is due to the size of the 
nanoparticles being similar (Figure 2A).  We believe that the level of DSF protection 
is based on a number of factors: 1) the size of the nanoparticles, 2) the overall 
surface area of the nanoparticle formulation and 3) the permeability of the 
nanoparticles. Therefore, the bigger the nanoparticle the greater the protection they 
provide due to the Cu having further to diffuse to have access to the DSF and the 
overall surface area being lower.  This is demonstrated by the fact that as the PVA 
loading, PVA molecular weight and sonication time are increased the level of 
protection from Cu each nanoparticle formulation provides is decreased (Figure 4A 
and 4B).  This correlates with a decrease in particle size (Figure 2A and 2B) and an 
increase in the surface area of the nanoparticle formulation.  Furthermore, the level 
of protection provided by the nanoparticle formulation that had a 9 minute sonication 
time is significantly lower than all of the other nanoparticle formulations (Figure 4A 
and 4B).  This is due to not only the decreased particle size and increased surface 
area, but also to the increased permeability of the PLGA caused by premature 
degradation as a result of the increased sonication time.     
3.5. The ability of the 10% w/w DSF-loaded PLGA nanoparticles to protect DSF from 
degradation in serum 
In order for DSF to have an anticancer effect it must first accumulate in the cancer 
cells in its unaltered form allowing it to chelate with copper. However, DSF has a 
very short half-life (4 minutes) in the bloodstream, which is limiting its anticancer 
application in the clinic.  Therefore, a drug delivery system which protects DSF from 
metabolism in the blood stream would expedite its translation into the clinic as a 
treatment for NSCLC.  We recently demonstrated that PLGA nanoparticles can 
extend the half-life of DSF in blood from under 2 minutes to 7 hours [46].  To further 
develop our DSF-loaded PLGA nanoparticles it is imperative that we understand how 
the choice of formulation and sonication time influences the ability of the PLGA 
nanoparticles to protect the DSF from degradation in the bloodstream.   
Figure 5 demonstrates that all of the DSF-loaded PLGA nanoparticle formulations 
significantly (p < 0.05) increased the half-life of DSF in serum in comparison to an 
unformulated DSF control.  The choice of PLGA had no significant (p > 0.05) 
influence on increasing the half-life of DSF in serum (Figure 5A).  All three PLGA 
polymers increased its half-life from approximately 3 minutes to 60 minutes, with 
approximately 40% of the DSF remaining after 120 minutes.  As with the protection 
of DSF form Cu, its level of protection in serum is also due to the size of the 
nanoparticles, their overall surface area and their permeability.  The PLGA coating 
protects the DSF from the serum for longer, thus increasing the half-life.  However, 
the fact that the choice of PLGA has no influence on the size of the nanoparticles 
(Figure 2A) and thus no influence on the overall surface area the level of protection 
is similar for each PLGA.  Furthermore, the PLGAs used had the same ratio of 
lactide to glycolide, similar molecular weights and the same sonication time was 
used to produce the nanoparticles.  Thus, the level of permeability of the 
nanoparticles would be similar, resulting in the level of protection of DSF being 
similar.      
The PVA loading and molecular weight had a significant influence (p < 0.05) on the 
increase in DSF half-life provided by the nanoparticles (Figure 5B and 5C).  The 2, 4 
and 8% w/w PVA loaded nanoparticles increased the half-life of DSF in serum from 
approximately 3 minutes to 120, 90 and 30 minutes respectively (Figure 5B).  The 
10, 75 and 120 KDa PVA nanoparticles increased the half-life of DSF in serum from 
3 minutes to 90, 55 and 22 minutes respectively (Figure 5C).    As mentioned 
previously the PLGA coating protects the DSF from the serum for longer, thus 
increasing the half-life.  The trend in the level of protection is associated with the size 
of the nanoparticles and their overall surface area.  Increasing both the PVA loading 
and molecular weight decreases the size of the nanoparticles (Figure 2A and 2B), 
which means that the serum has less distance to diffuse into the nanoparticle before 
it comes in contact with the DSF causing it to degrade.  Furthermore, the smaller the 
nanoparticles the greater their overall surface area, which increases the diffusion of 
the serum into them, decreasing the length of time it takes for it to access the DSF 
causing it to degrade.  
Increasing the sonication time significantly (p < 0.05) decreased the half-life of DS in 
the nanoparticles (Figure 5D).  At 3, 6 and 9 minute sonication time the nanoparticles 
increased the half-life of DSF in serum from approximately 3 minutes to 90, 20 and 
10 minutes respectively (Figure 5D).  As mentioned previously the decrease in DSF 
half-life is due to the decrease in the size of the nanoparticles and increase in their 
overall surface area.  However, the decrease in half-life at 6 minutes and 9 minutes 
was significantly greater than what would be expected based on the decrease in 
particle size and thus another factor must be coming into play.  We believe this factor 
to be the permeability of the PLGA.  It has been demonstrated that increasing the 
sonication time can cause the PLGA polymer to prematurely degrade increasing its 
permeability [62], increasing the diffusion rate of the serum into the nanoparticle 
decreasing the length of time it takes for it to access the DSF causing it to degrade. 
3.6. The cytotoxicity of the 10% w/w DSF-loaded PLGA nanoparticles against 
NSCLC cells 
The cytotoxicity of the 10% w/w DSF-loaded PLGA nanoparticles against NSCLC is 
presented in figure 6.  The figure demonstrates that all of the nanoparticle 
formulations are cytotoxic against NSCLC.  However, their IC50 is significantly (p < 
0.05) greater than that of free DSF (7.6nM).  The choice of PLGA had no significant 
(p > 0.05) effect on the cytotoxicity of the nanoparticles with DLG 1E, 4A and 4E 
having an IC50 values of 14.6, 16.1 and 16.1nM respectively (Figure 6A).  An 
increase in PVA loading increased the cytotoxicity of the nanoparticle formulations, 
with the 2, 4 and 8% w/w loadings having IC50 values of 32.3, 16.2 and 13.4 
respectively (Figure 6B).  Increasing the molecular weight of the PVA also increased 
the cytotoxicity of the nanoparticle formulations (Figure 6C).  The 10, 75 and 120 
KDa PVA nanoparticles had IC50 values of 25.8, 16.2 and 11.5 respectively.  An 
increase in sonication time increased the cytotoxicity of the nanoparticle 
formulations, with the 3, 6 and 9 minute sonication times having IC50 values of 16.2, 
10.2 and 9.8 respectively (Figure 6D). 
This trend in cytotoxicity is predominately controlled by the particle size of the 
nanoparticles, which is demonstrated by a linear relationship between particle size 
and IC50 value (Figure 6E).  However, we believe that the permeability of the 
nanoparticles is also playing a part, particularly for those with a 6 and 9 minute 
sonication time.  The nanoparticles with a 6 minute sonication time had a similar 
particle size (152.7 nm) to the 8% w/w PVA nanoparticles (150.6) but had a 
significantly (p < 0.05) lower IC50 value, 10.2 compared to 13.4 nM, making them 
more cytotoxic.  The same trend occurs with those nanoparticles sonicated for 9 
minutes.  They had a particle size of 145.2 nm, while the nanoparticles containing 
PVA with a molecular weight of 120 KDa had a particle size of 145.9 nm.  However, 
the nanoparticles sonicated for 9 minutes had an IC50 value of 9.8, while those 
containing PVA with a molecular weight of 12oKDa had an IC50 value of 11.5 nM.  
We believe that the extra 3 and 6 minutes of sonication caused the PLGA to 
prematurely degrade, increasing their permeability, which increased the diffusion of 
DSF out the nanoparticles resulting in a greater concentration of DSF inside the 
NSCLC cells increasing cell death.  This is further demonstrated by the fact that the 
nanoparticles sonicated for 6 and 9 minutes provided the highest release rate of DSF 
(Figure 3).       
4. Conclusion 
This paper investigates the influence of PLGA type, PVA loading and molecular 
weight as well as sonication time on the morphology, particle size, zeta potential, 
encapsulation efficiency, DSF release, protection from copper, protection from 
degradation in serum and cytotoxicity of 10% w/w DSF-loaded PLGA nanoparticles.  
The choice of PLGA polymer had no significant influence on the any of the 
nanoparticle characteristics except for DSF release, which was due to the varying 
degradation times of the PLGAs.  Increasing both the PVA loading and molecular 
weight decreased the size of the nanoparticles, which in turn increased the overall 
surface area of the nanoparticle formulation.  The decrease in particle size and 
increase in overall surface area reduced the ability of the nanoparticles to protect the 
DSF from reacting with Cu and degradation in serum, while increasing their DSF 
release rate and cytotoxicity.  Increasing the sonication time also decreased the size 
of the nanoparticles and thus increased their overall surface area.  Like increasing 
PVA loading and molecular weight this resulted in a decrease in the protection of 
DSF from reacting with Cu and degradation in serum, while increasing their DSF 
release and cytotoxicity.  Additionally, increasing the sonication time resulted in the 
premature degradation of the PLGA, which increased the permeability of the 
nanoparticles.  This increase in permeability further decreased their ability to protect 
DSF from reacting with Cu and degradation in serum, while further increasing their 
DSF release rate and cytotoxicity.  We have recently demonstrated that a low dose 
of DSF-loaded PLGA nanoparticles supplemented with oral Cu inhibited tumour 
growth and reduced metastasis in a xenograft mouse lung cancer model.  This paper 
demonstrates the influence of the various formulation parameters and sonication 
time on the characteristics and cytotoxicity of the DSF-loaded PLGA nanoparticles, 
which will allow us to produce the most stable and cytotoxic nanoparticle formulation.  
Furthermore, this research will inform the scale-up and full scale manufacture of a 
DSF-loaded nanoparticle formulation expediting its translation from the lab into the 
clinic.   
  
Figure Captions      
Figure 1: Representative SEM image of the 10% w/w DSF-loaded PLGA 
nanoparticles 
Figure 2: Particle size (A and B) and encapsulation efficiency (C and D) of the 10% 
w/w DSF-loaded PLGA nanoparticles 
Figure 3: In vitro drug release for the 10% w/w DSF-loaded PLGA nanoparticles 
prepared using different PLGA polymers (A), PVA loadings (B), PVA molecular 
weights (C) and sonication times (D). 
Figure 4: The influence of PLGA polymer and PVA loading (A) and well as PVA 
molecular weight and sonication time (B) on the ability of the 10% w/w DSF-loaded 
nanoparticles to protect DSF from reacting with Cu 
Figure 5: The influence of PLGA polymer (A), PVA loading (B), PVA molecular 
weight (C) and sonication time (D) on the ability of the 10% w/w DSF-loaded 
nanoparticles to protect DSF from degradation in serum. 
Figure 6: The influence of PLGA polymer (A), PVA loading (B), PVA molecular 
weight (C) and sonication time (D) on the cytotoxicity of the 10% w/w DSF-loaded 
nanoparticles in comparison to a DSF control.  The relationship between particle size 
and the IC50 value of the10% w/w DSF-loaded nanoparticles (E).  
Table Captions 
Table 1: The formulation variables and sonication times of the 10% w/w DSF-loaded 
PLGA nanopartilces. 
Table 2: Particle size and Zeta potentials for the 10% w/w DSF-loaded 
nanoparticles. 
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